This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The outcomes estimated from the literature were test sensitivity and specificity, the probability of drug side effects, and the probability of influenza complications.
Study designs and other criteria for inclusion in the review
It was not stated whether a systematic review of the literature was undertaken to identify relevant primary studies. No information on the design and characteristics of the primary studies was reported.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Eleven primary studies provided evidence.
Methods of combining primary studies
Average values were calculated when multiple sources were available.
Investigation of differences between primary studies
Results of the review
The sensitivity of the test was 72.5% (range: 50 -95) and the specificity was 90% (range: 80 -100).
The probability of drug side effects was 3% (range: 0 -6).
The probability of influenza complications was 0.5 (range: 0.3 -5).
Methods used to derive estimates of effectiveness
A key assumption on the efficacy of anti-influenza treatment was made.
Estimates of effectiveness and key assumptions
It was assumed that patients receiving anti-influenza treatment would return to work one day earlier than patients receiving no treatment.
Measure of benefits used in the economic analysis
The summary benefit measure was the increase in productivity. This was based on the patient being able to return to work earlier because of the beneficial effect of treatment (as estimated already). The unit cost of productivity gains was based on the hourly wage plus the benefits for a worker in the USA.
Direct costs
Discounting was not relevant since the costs were incurred during a short timeframe (one month). Some unit costs were presented separately from the quantities of resources used. The economic evaluation considered diagnostic tests, medications, outpatient visits, the treatment of adverse events, and insurance co-payments for hospital or outpatient services. The cost of the initial visit to the clinician was not considered since all patients would have already incurred this expense. The cost/resource boundary of the health care system and the patient was adopted in the analysis of the direct costs. The cost of a visit for diagnostic codes for influenza was estimated by calculating the weighted average visit costs for respiratory tract infections. Other resource use data were derived from authors' opinions and published evidence. The costs came from reimbursement rates, average wholesale prices, hospital sources and published data. Diagnostic tests costs were based on the average cost of five currently commercially available test kits. All of the costs were adjusted to 2002 values using the medical component of the Consumer Price Index.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs (i.e. productivity losses) were not considered on the cost side of the analysis.
Currency

US dollars ($).
Sensitivity analysis
Univariate sensitivity analyses were carried out on all model inputs to examine the robustness of the base-case results to variations in base-case assumptions. Two-way sensitivity analyses were also performed on some key inputs. The results were presented as threshold analyses representing the point at which the economic value assigned to an earlier recovery altered the decision for the entire range of pre-test probabilities. The ranges of values used were mainly derived from the literature.
Estimated benefits used in the economic analysis
The estimated benefits were not reported.
Cost results
The estimated costs were not reported.
Synthesis of costs and benefits
A cost-benefit ratio was calculated to combine the economic costs and benefits of the alternative diagnostic and treatment strategies under examination. As already stated, the results were presented using a threshold analysis.
